References
- Brown A, Elmhirst E, Vantage 2020 Preview; 2020.
- Jardim DL, Groves ES, Breitfeld PP, et al. Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. Cancer Treat Rev. 2017;52:12–21.
- Visser SAG, Bueters TJH. Assessment of translational risk in drug research: role of biomarker classification and mechanism-based PKPD concepts. Eur J Pharm Sci. 2017;109S:S72–S77.
- Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers: a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes. AAPS J. 2008;10(2):401–409.
- Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16(5):275–287.
- Wang Y, Zhu H, Madabushi R, et al. Model-informed drug development: current US regulatory practice and future considerations. Clin Pharmacol Ther. 2019;105(4):899–911.
- Nayak S, Sander O, Al-Huniti N, et al. Getting innovative therapies faster to patients at the right dose: impact of quantitative pharmacology towards first registration and expanding therapeutic use. Clin Pharmacol Ther. 2018;103(3):378–383.
- Sachs JR, Mayawala K, Gadamsetty S, et al. Optimal dosing for targeted therapies in oncology: drug development cases leading by example. Clin Cancer Res. 2016;22(6):1318–1324.
- Shebley M, Sandhu P, Emami Riedmaier A, et al. Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective. Clin Pharmacol Ther. 2018;104(1):88–110.
- Wang YH, Chen D, Hartmann G, et al. PBPK modeling strategy for predicting complex drug interactions of letermovir as a perpetrator in support of product labeling. Clin Pharmacol Ther. 2019;105(2):515–523.
- Bradshaw EL, Spilker ME, Zang R, et al. Applications of quantitative systems pharmacology in model-informed drug discovery: perspective on impact and opportunities. CPT Pharmacometrics Syst Pharmacol. 2019;8(11):777–791.
- Venkatakrishnan K, Friberg LE, Ouellet D, et al. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities. Clin Pharmacol Ther. 2015;97(1):37–54.
- Bottino DC, Patel M, Kadakia E, et al. Dose optimization for anticancer drug combinations: maximizing therapeutic index via clinical exposure-toxicity/preclinical exposure-efficacy modeling. Clin Cancer Res. 2019;25(22):6633–6643.
- Morgan P, Brown DG, Lennard S, et al. Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17(3):167–181.